Kineta to Present at Upcoming Investor Conferences

Rhea-AI Summary

Kineta, Inc. (KA) announces its participation in upcoming investors conferences to present its novel immunotherapies in oncology. The Company will attend BIO CEO and Investor Conference, 10th Annual Immuno-Oncology 360 Conference, and Opal Group Family Office Winter Forum for presentations and 1:1 meetings.

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the Company will be attending and presenting at the following upcoming investors conferences:

BIO CEO and Investor Conference
Date:   Monday, February 26, 2024
Time:   9:45 A.M.– 10:00 A.M. Eastern Time
Format: Presentation and 1:1 meetings
Location: The New York Marriott Marquis, Uris room

10th Annual Immuno-Oncology 360 Conference (IO360)
Date: February 27-29, 2024
Format: 1:1 meetings
Location: New York Marriott at the Brooklyn Bridge

Opal Group Family Office Winter Forum
Date:   Monday, March 4, 2024
Time:   12:30 P.M.– 12:50 P.M. Eastern Time
Format: Presentation and 1:1 meetings
Location: etc.venues 360 Madison, New York, NY

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

About Kineta
Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on X (Twitter), LinkedIn and Facebook.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Kineta, Inc.:
Jacques Bouchy
EVP Investor Relations & Business Development
+1 206-378-0400
jbouchy@kineta.us

Investor Relations:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

Source: Kineta, Inc.

FAQ

When is Kineta, Inc. (KA) attending the BIO CEO and Investor Conference?

Kineta, Inc. (KA) will be attending the BIO CEO and Investor Conference on Monday, February 26, 2024.

Where will Kineta, Inc. (KA) be presenting at the 10th Annual Immuno-Oncology 360 Conference?

Kineta, Inc. (KA) will be presenting at the 10th Annual Immuno-Oncology 360 Conference at the New York Marriott at the Brooklyn Bridge.

What is the format of Kineta, Inc. (KA) presentation at the Opal Group Family Office Winter Forum?

The format of Kineta, Inc. (KA) presentation at the Opal Group Family Office Winter Forum will be a presentation and 1:1 meetings on Monday, March 4, 2024.

How can interested investors schedule meetings with Kineta, Inc. (KA) during the conferences?

Interested investors should contact their respective representative at the sponsoring institutions to request one-on-one meetings with Kineta, Inc. (KA) during the conferences.